Trial Profile
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jun 2021
Price :
$35
*
At a glance
- Drugs Galcanezumab (Primary) ; Nonsteroidal anti-inflammatories; Paracetamol; Sumatriptan; Sumatriptan; Sumatriptan; Zolmitriptan; Zolmitriptan
- Indications Cluster headache
- Focus Registrational; Therapeutic Use
- Acronyms CGAL
- Sponsors Eli Lilly and Company
- 22 Apr 2021 Results (n=39 from CGAL, NCT02397473 who enrolled in CGAR, NCT02797951) assessing consistency of effect with galcanezumab for episodic cluster headache (ECH) across multiple cluster periods,presented at the 73rd Annual Meeting of the American Academy of Neurology
- 25 Feb 2021 According to a Eli Lilly Canada Inc media release, Emgality (galcanezumab) is approved for use in Canada for the treatment of episodic cluster headache.
- 11 Nov 2020 Results of a post hoc analysis assessing the treatment outcome in terms of median time-to-first occurrence of more than or equal to 50, more than or equal to 75, or 100% reduction from baseline in CH attack frequency, and impact on acute medication usepublished in the Headache